COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0AG8C
|
|||
Drug Name |
GC376
|
|||
Synonyms |
CS-6923; HY-100721; CHEMBL2315036
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Investigative | [1] | Middle East Respiratory Syndrome (MERS) | Preclinical | [2] | Severe acute respiratory syndrome (SARS) | Preclinical | [2] |
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
Download2D MOL |
|||
Formula |
C21H30N3NaO8S
|
|||
Canonical SMILES |
CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2=CC=CC=C2.[Na+]
|
|||
InChI |
1S/C21H31N3O8S.Na/c1-13(2)10-16(24-21(28)32-12-14-6-4-3-5-7-14)19(26)23-17(20(27)33(29,30)31)11-15-8-9-22-18(15)25;/h3-7,13,15-17,20,27H,8-12H2,1-2H3,(H,22,25)(H,23,26)(H,24,28)(H,29,30,31);/q;+1/p-1/t15?,16-,17-,20?;/m0./s1
|
|||
InChIKey |
BSPJDKCMFIPBAW-JPBGFCRCSA-M
|
|||
CAS Number |
CAS 1416992-39-6
|
|||
PubChem Compound ID |
Target | Top | |||
---|---|---|---|---|
Target(s) | COVID-19 3C-like protease (3CLpro) | Target Info | Inhibitor | [1] |
The activity of GC376 against SARS-CoV-2 main protease (Mpro) has been successfully determined using the FRET-based enzymatic assay. | ||||
MERS-CoV 3C-like proteinase (3CLpro) | Target Info | Inhibitor | [2] | |
GC376 is found to inhibit MERS-CoV 3CLpro protease illuminated by using a FRET assay. | ||||
SARS-CoV 3C-like protease (3CLpro) | Target Info | Inhibitor | [2] | |
The activity of GC376 against the 3CLpro of SARS-CoV has been successfully determined using a FRET assay. |
References | Top | |||
---|---|---|---|---|
1 | Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. 2020. April 20. doi: https://doi.org/10.1101/2020.04.20.051581 | |||
2 | Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. PLoS Pathog. 2016 Mar 30;12(3):e1005531. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.